



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mauler-Machnik *et al.*

Appl. No.: 10/576,181

Filed: July 26, 2006

For: **Fungicidal Active Combinations  
Spiroxamine, Prothioconazole and  
Tebuconazole**

Confirmation No.: 7330

Art Unit: 1616

Examiner: Brooks, Kristie L.

**Declaration of Peter Dahmen Under 37 C.F.R. §1.132**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

I, Peter Dahmen, of Altebrücker Str. 61, 41470 Neuss, Germany, a citizen  
of Germany, hereby declare:

1. that I am a biologist having studied at the University of Bonn, Germany;
2. that I received the degree of Dr. agr. at the University of Bonn, Germany;
3. that I entered the employ of Bayer Aktiengesellschaft, Leverkusen, in  
1991, where I have been employed in the department of Biology Herbicides, that after  
the spin-off from Bayer CropScience AG I am now employee of this company in the  
department of Global Biology Fungicides;
4. that I have specialized in the field of fungicide research;
5. that the following tests have been carried out under my supervision and  
control.

**Comparative Test**

*Fusarium graminearum* test (barley) / preventive

Solvent: 49 parts by weight of N,N-dimethyl acetamide

Emulsifier: 1 parts by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound combination at the stated rate of application. After the spray coating has been dried, the plants are sprayed with a suspension of spores of *Fusarium graminearum*. The plants are placed in a greenhouse chamber under a translucent incubation hood at a temperature of 22°C and a relative atmospheric humidity of 100 %.

The test is evaluated 5 days after the inoculation. 0 % means an efficacy which corresponds to that of the control, while an efficacy of 100 % means that no disease is observed.

Results: *Fusarium graminearum* test (barley) / preventive

Active compound combination	Mixing ratio	Application rate of active compound in ppm	Efficacy in %
<u>Known from WO 96/41533:</u> Tebuconazole + Propiconazole + Spiroxamine	3,9 : 1 : 5.8	167 + 43 + 250	40
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine (Mixing ratio identical to ratio in WO 96/41533)	3,9 : 1 : 5.8	167 + 43 + 250	80
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine	1 : 1 : 2.5	100 + 100 + 250	100

Active compound combination	Mixing ratio	Application rate of active compound in ppm	Efficacy in %
<u>Known from WO 96/38040:</u> Tebuconazole + Triadimenol + Spiroxamine	3,9 : 1 : 5.8	167 + 43 + 250	60
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine (Mixing ratio identical to ratio in WO 96/41533)	3,9 : 1 : 5.8	167 + 43 + 250	80
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine	1 : 1 : 2.5	100 + 100 + 250	100

Reply to Office Action of September 23, 2008

Mauler-Machnik *et al.*  
Appl. No. 10/576,181

Active compound combination	Mixing ratio	Application rate of active compound in ppm	Efficacy in %
<u>Known from WO 96/38040:</u> Tebuconazole + Triadimefon + Spiroxamine	3,9 : 1 : 5.8	167 + 43 + 250	40
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine (Mixing ratio identical to ratio in WO 96/41533)	3,9 : 1 : 5.8	167 + 43 + 250	80
<u>According to the invention:</u> Tebuconazole + Prothioconazole + Spiroxamine	1 : 1 : 2.5	100 + 100 + 250	100

The undersigned declarant declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed at Monheim, Germany,

2008-10-31

Date



Dr. Peter Dahmen